Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

Summary

The objective are to assess the nature and incidence of drug intolerance observed with a new antiretroviral triple therapy, Truvada® \[0-0-1\] + Isentress® 400 mg tablets \[1-0-1\], prescribed in a setting of the treatment of individuals with recent exposure to a risk of transmission of HIV infection and to compare the results with those of previous studies conducted according to the same methodology, with other combinations of antiretrovirals.

Timeline

Start

2010-11-01

Primary completion

2012-08-01

Completion

2012-12-01

Drugs

Indications